{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:39:35Z","timestamp":1770298775708,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Danish Council for Independent Reserach - Medical Sciences","award":["DFF-6110-00533"],"award-info":[{"award-number":["DFF-6110-00533"]}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"crossref","award":["NNF14OC0011019"],"award-info":[{"award-number":["NNF14OC0011019"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"name":"EPFL Fellows","award":["665667"],"award-info":[{"award-number":["665667"]}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["CTQ2017-83810-R"],"award-info":[{"award-number":["CTQ2017-83810-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI13\/00090"],"award-info":[{"award-number":["PI13\/00090"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","award":["S2010\/BMD-2312"],"award-info":[{"award-number":["S2010\/BMD-2312"]}],"id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00262-018-2181-5","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T12:22:24Z","timestamp":1528114944000},"page":"1251-1260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3583-6102","authenticated-orcid":false,"given":"Kasper","family":"M\u00f8lgaard","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-7813","authenticated-orcid":false,"given":"Seandean L.","family":"Harwood","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7138-9266","authenticated-orcid":false,"given":"Marta","family":"Compte","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0721-4813","authenticated-orcid":false,"given":"Nekane","family":"Merino","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5210-4387","authenticated-orcid":false,"given":"Jaume","family":"Bonet","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-5447","authenticated-orcid":false,"given":"Ana","family":"Alvarez-Cienfuegos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6062-4243","authenticated-orcid":false,"given":"Kasper","family":"Mikkelsen","sequence":"additional","affiliation":[]},{"given":"Natalia","family":"Nu\u00f1ez-Prado","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-7730","authenticated-orcid":false,"given":"Ana","family":"Alvarez-Mendez","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-3218","authenticated-orcid":false,"given":"Laura","family":"Sanz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2545-4319","authenticated-orcid":false,"given":"Francisco J.","family":"Blanco","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3053-6757","authenticated-orcid":false,"given":"Luis","family":"Alvarez-Vallina","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"key":"2181_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1745-7254.2005.00008.x","volume":"26","author":"RE Kontermann","year":"2005","unstructured":"Kontermann RE (2005) Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26:1\u20139. https:\/\/doi.org\/10.1111\/j.1745-7254.2005.00008.x","journal-title":"Acta Pharmacol Sin"},{"key":"2181_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.drudis.2015.02.013","volume":"20","author":"N Nu\u00f1ez-Prado","year":"2015","unstructured":"Nu\u00f1ez-Prado N, Compte M, Harwood S et al (2015) The coming of age of engineered multivalent antibodies. Drug Discov Today 20:588\u2013594. https:\/\/doi.org\/10.1016\/j.drudis.2015.02.013","journal-title":"Drug Discov Today"},{"key":"2181_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann RE, Brinkmann U (2015) Bispecific antibodies. Drug Discov Today 20:838\u2013847. https:\/\/doi.org\/10.1016\/j.drudis.2015.02.008","journal-title":"Drug Discov Today"},{"key":"2181_CR4","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"A L\u00f6ffler","year":"2000","unstructured":"L\u00f6ffler A, Kufer P, Lutterb\u00fcse R et al (2000) A recombinant bispecific single-chain antibody, CD19 \u00d7 CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098\u20132103","journal-title":"Blood"},{"key":"2181_CR5","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G et al (2012) Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood 119:6226\u20136233. https:\/\/doi.org\/10.1182\/blood-2012-01-400515","journal-title":"Blood"},{"key":"2181_CR6","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.4049\/jimmunol.171.2.1070","volume":"171","author":"B Blanco","year":"2003","unstructured":"Blanco B, Holliger P, Vile RG et al (2003) Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 171:1070\u20131077. https:\/\/doi.org\/10.4049\/jimmunol.171.2.1070","journal-title":"J Immunol"},{"key":"2181_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/sj.cgt.7701021","volume":"14","author":"M Compte","year":"2007","unstructured":"Compte M, Blanco B, Serrano F et al (2007) Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA \u00d7 anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 14:380\u2013388. https:\/\/doi.org\/10.1038\/sj.cgt.7701021","journal-title":"Cancer Gene Ther"},{"key":"2181_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1634\/stemcells.2008-0831","volume":"27","author":"M Compte","year":"2009","unstructured":"Compte M, Cuesta AM, S\u00e1nchez-Mart\u00edn D et al (2009) Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 27:753\u2013760. https:\/\/doi.org\/10.1634\/stemcells.2008-0831","journal-title":"Stem Cells"},{"key":"2181_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/gt.2010.33","volume":"17","author":"M Compte","year":"2010","unstructured":"Compte M, Alonso-Camino V, Santos-Valle P et al (2010) Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene Ther 17:745\u2013751. https:\/\/doi.org\/10.1038\/gt.2010.33","journal-title":"Gene Ther"},{"key":"2181_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/gt.2017.3","volume":"24","author":"K M\u00f8lgaard","year":"2017","unstructured":"M\u00f8lgaard K, Compte M, Nu\u00f1ez-Prado N et al (2017) Balanced secretion of anti-CEA \u00d7 anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity. Gene Ther 24:208\u2013214. https:\/\/doi.org\/10.1038\/gt.2017.3","journal-title":"Gene Ther"},{"key":"2181_CR11","doi-asserted-by":"publisher","first-page":"e28810","DOI":"10.4161\/onci.28810","volume":"3","author":"M Compte","year":"2014","unstructured":"Compte M, Alvarez-Cienfuegos A, Nu\u00f1ez-Prado N et al (2014) Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications. Oncoimmunology 3:e28810. https:\/\/doi.org\/10.4161\/onci.28810","journal-title":"Oncoimmunology"},{"key":"2181_CR12","doi-asserted-by":"publisher","first-page":"e1377874","DOI":"10.1080\/2162402X.2017.1377874","volume":"7","author":"SL Harwood","year":"2017","unstructured":"Harwood SL, Alvarez-Cienfuegos A, Nu\u00f1ez-Prado N et al (2017) ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology 7:e1377874. https:\/\/doi.org\/10.1080\/2162402X.2017.1377874","journal-title":"Oncoimmunology"},{"key":"2181_CR13","doi-asserted-by":"publisher","first-page":"28643","DOI":"10.1038\/srep28643","volume":"6","author":"A Alvarez-Cienfuegos","year":"2016","unstructured":"Alvarez-Cienfuegos A, Nu\u00f1ez-Prado N, Compte N et al et al (2016) Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. Sci Rep 6:28643. https:\/\/doi.org\/10.1038\/srep28643","journal-title":"Sci Rep"},{"key":"2181_CR14","doi-asserted-by":"publisher","first-page":"5.6.15.6.37","DOI":"10.1002\/cpbi.3","volume":"54","author":"B Webb","year":"2016","unstructured":"Webb B, Sali A (2016) Comparative protein structure modeling using MODELLER. Curr Protoc Bioinform 54:5.6.1\u20135.6.37. https:\/\/doi.org\/10.1002\/cpbi.3","journal-title":"Curr Protoc Bioinform"},{"key":"2181_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4161\/mabs.22698","volume":"5","author":"A Blanco-Toribio","year":"2013","unstructured":"Blanco-Toribio A, Sainz-Pastor N, Alvarez-Cienfuegos A et al (2013) Generation and characterization of monospecific and bispecific hexavalent trimerbodies. MAbs 5:70\u201379. https:\/\/doi.org\/10.4161\/mabs.22698","journal-title":"MAbs"},{"key":"2181_CR16","doi-asserted-by":"publisher","first-page":"34515","DOI":"10.1038\/srep34515","volume":"6","author":"JH Kim","year":"2016","unstructured":"Kim JH, Song DH, Youn SJ et al (2016) Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface. Sci Rep 6:34515. https:\/\/doi.org\/10.1038\/srep34515","journal-title":"Sci Rep"},{"key":"2181_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/1471-2105-10-421","volume":"10","author":"C Camacho","year":"2009","unstructured":"Camacho C, Coulouris G, Avagyan V et al (2009) BLAST+: architecture and applications. BMC Bioinform 10:421. https:\/\/doi.org\/10.1186\/1471-2105-10-421","journal-title":"BMC Bioinform"},{"key":"2181_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1042\/bj3460519","volume":"346","author":"MK Boehm","year":"2000","unstructured":"Boehm MK, Corper AL, Wan T et al (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 346:519\u2013528","journal-title":"Biochem J"},{"key":"2181_CR19","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.str.2013.05.008","volume":"21","author":"KR Schmitz","year":"2013","unstructured":"Schmitz KR, Bagchi A, Roovers RC et al (2013) Structural evaluation of EGFR inhibition mechanisms for nanobodies\/VHH domains. Structure 21:1214\u20131224. https:\/\/doi.org\/10.1016\/j.str.2013.05.008","journal-title":"Structure"},{"key":"2181_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1126\/science.314668","volume":"206","author":"P Kung","year":"1979","unstructured":"Kung P, Goldstein G, Reinherz EL et al (1979) Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206:347\u2013349","journal-title":"Science"},{"key":"2181_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL (2015) Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 93:290\u2013296. https:\/\/doi.org\/10.1038\/icb.2014.93","journal-title":"Immunol Cell Biol"},{"key":"2181_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S (2013) Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82:775\u2013797. https:\/\/doi.org\/10.1146\/annurev-biochem-063011-092449","journal-title":"Annu Rev Biochem"},{"key":"2181_CR23","doi-asserted-by":"publisher","first-page":"7346","DOI":"10.1074\/jbc.M007734200","volume":"276","author":"K Els Conrath","year":"2001","unstructured":"Els Conrath K, Lauwereys M, Wyns L et al (2001) Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 276:7346\u20137350. https:\/\/doi.org\/10.1074\/jbc.M007734200","journal-title":"J Biol Chem"},{"key":"2181_CR24","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CJI.0000000000000099","volume":"38","author":"L Li","year":"2015","unstructured":"Li L, He P, Zhou C et al (2015) A novel bispecific antibody, S-Fab, induces potent cancer cell killing. J Immunother 38:350\u2013356. https:\/\/doi.org\/10.1097\/CJI.0000000000000099","journal-title":"J Immunother"},{"key":"2181_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13568-016-0201-4","volume":"6","author":"A Li","year":"2016","unstructured":"Li A, Xing J, Li L et al (2016) A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells. AMB Express 6:32. https:\/\/doi.org\/10.1186\/s13568-016-0201-4","journal-title":"AMB Express"},{"key":"2181_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/jb\/mvh065","volume":"135","author":"XB Wang","year":"2004","unstructured":"Wang XB, Zhao BF, Zhao Q et al (2004) A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently. J Biochem 135:555\u2013565. https:\/\/doi.org\/10.1093\/jb\/mvh065","journal-title":"J Biochem"},{"key":"2181_CR27","doi-asserted-by":"publisher","first-page":"385397","DOI":"10.2174\/1566523013348418","volume":"1","author":"L Alvarez-Vallina","year":"2001","unstructured":"Alvarez-Vallina L (2001) Genetic approaches for antigen-selective cell therapy. Curr Gene Ther 1:385\u2013397. https:\/\/doi.org\/10.2174\/1566523013348418","journal-title":"Curr Gene Ther"},{"key":"2181_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.it.2003.12.001","volume":"25","author":"L Sanz","year":"2004","unstructured":"Sanz L, Blanco B, Alvarez-Vallina L (2004) Antibodies and gene therapy: teaching old \u2018magic bullets\u2019 new tricks. Trends Immunol 25:85\u201391. https:\/\/doi.org\/10.1016\/j.it.2003.12.001","journal-title":"Trends Immunol"},{"key":"2181_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/mt.2014.156","volume":"23","author":"K Iwahori","year":"2015","unstructured":"Iwahori K, Kakarla S, Velasquez MP et al (2015) Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 23:171\u2013178. https:\/\/doi.org\/10.1038\/mt.2014.156","journal-title":"Mol Ther"},{"key":"2181_CR30","doi-asserted-by":"publisher","first-page":"27130","DOI":"10.1038\/srep27130","volume":"6","author":"MP Velasquez","year":"2016","unstructured":"Velasquez MP, Torres D, Iwahori K et al (2016) T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive malignancies. Sci Rep 6:27130. https:\/\/doi.org\/10.1038\/srep27130","journal-title":"Sci Rep"},{"key":"2181_CR31","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/mt.2016.116","volume":"24","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Szoor A, Torres D et al (2016) CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia. Mol Ther 24:1615\u20131626. https:\/\/doi.org\/10.1038\/mt.2016.116","journal-title":"Mol Ther"},{"key":"2181_CR32","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1038\/bcj.2016.38","volume":"6","author":"X Liu","year":"2016","unstructured":"Liu X, Barrett DM, Jiang S et al (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430. https:\/\/doi.org\/10.1038\/bcj.2016.38","journal-title":"Blood Cancer J"},{"key":"2181_CR33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nm.4356","volume":"23","author":"CR Stadler","year":"2017","unstructured":"Stadler CR, B\u00e4hr-Mahmud H, Celik L et al (2017) Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med 23:815\u2013817. https:\/\/doi.org\/10.1038\/nm.4356","journal-title":"Nat Med"},{"key":"2181_CR34","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/1078-0432.CCR-07-4465","volume":"14","author":"JH Baker","year":"2008","unstructured":"Baker JH, Lindquist KE, Huxham LA et al (2008) Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 14:2171\u20132179. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4465","journal-title":"Clin Cancer Res"},{"key":"2181_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cbpa.2013.03.029","volume":"17","author":"SR Frankel","year":"2013","unstructured":"Frankel SR, Baeuerle PA (2013) Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 17:385\u2013392. https:\/\/doi.org\/10.1016\/j.cbpa.2013.03.029","journal-title":"Curr Opin Chem Biol"},{"key":"2181_CR36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","volume":"6","author":"K Rezvani","year":"2015","unstructured":"Rezvani K, Rouce RH (2015) The application of Natural Killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578. https:\/\/doi.org\/10.3389\/fimmu.2015.00578","journal-title":"Front Immunol"},{"key":"2181_CR37","first-page":"3639","volume":"23","author":"S Yano","year":"2003","unstructured":"Yano S, Kondo K, Yamaguchi M et al (2003) Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23:3639\u20133650","journal-title":"Anticancer Res"},{"key":"2181_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2174\/156800912800190956","volume":"12","author":"A Ballestrero","year":"2012","unstructured":"Ballestrero A, Garuti A, Cirmena G et al (2012) Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr Cancer Drug Targets 12:316\u2013328. https:\/\/doi.org\/10.2174\/156800912800190956","journal-title":"Curr Cancer Drug Targets"},{"key":"2181_CR39","doi-asserted-by":"publisher","first-page":"12605","DOI":"10.1073\/pnas.1000976107","volume":"107","author":"R Lutterbuese","year":"2010","unstructured":"Lutterbuese R, Raum T, Kischel R et al (2010)) T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A 107:12605\u201312610. https:\/\/doi.org\/10.1073\/pnas.1000976107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2181_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.tibtech.2015.02.008","volume":"33","author":"D Sanchez-Martin","year":"2015","unstructured":"Sanchez-Martin D, S\u00f8rensen MD, Lykkemark S et al (2015) Selection strategies for anticancer antibody discovery: searching off the beaten path. Trends Biotechnol 33:292\u2013301. https:\/\/doi.org\/10.1016\/j.tibtech.2015.02.008","journal-title":"Trends Biotechnol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2181-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T22:02:11Z","timestamp":1571436131000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2181-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2181-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,4]]},"assertion":[{"value":"2 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving human blood products were in accordance with the ethical standards of the Aarhus University Hospital Ethical Committee and with the 1964 Helsinki declaration and its later amendments. Human peripheral blood mononuclear cells were isolated from fresh peripheral blood of anonymized healthy volunteer donors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Blood donors were recruited to donate blood by standard phlebotomy. The investigational nature of the studies in which their blood would be used, and the risks and discomforts of the donation process were carefully explained to the donors, and a signed informed consent document was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}